Grade 3/4 adverse events in fully supplemented versus never supplemented patients treated with pemetrexed plus cisplatin
| Adverse events . | Fully supplemented, % (n = 168) . | Never supplemented, % (n = 32) . |
|---|---|---|
| Neutrophils/granulocytes | 24.4 | 37.5 |
| Fatigue | 17.3 | 31.3 |
| Leukocytes | 15.5 | 34.4 |
| Nausea | 11.9 | 31.3 |
| Dyspnea | 11.3 | 12.5 |
| Hypertension | 11.3 | 3.1 |
| Vomiting | 10.7 | 34.4 |
| Chest pain | 8.3 | 6.3 |
| Hemoglobin | 6.0 | 9.4 |
| Thrombosis/embolism | 6.0 | 3.1 |
| Platelets | 5.4 | 9.4 |
| Tumor pain | 4.8 | 6.3 |
| Dehydration | 4.2 | 9.4 |
| Constipation | 3.6 | 3.1 |
| Diarrhea without colostomy | 3.6 | 9.4 |
| Febrile neutropenia | 0.6 | 9.4 |
| Infection with grade3/4 neutropenia | 0.6 | 6.3 |
| Adverse events . | Fully supplemented, % (n = 168) . | Never supplemented, % (n = 32) . |
|---|---|---|
| Neutrophils/granulocytes | 24.4 | 37.5 |
| Fatigue | 17.3 | 31.3 |
| Leukocytes | 15.5 | 34.4 |
| Nausea | 11.9 | 31.3 |
| Dyspnea | 11.3 | 12.5 |
| Hypertension | 11.3 | 3.1 |
| Vomiting | 10.7 | 34.4 |
| Chest pain | 8.3 | 6.3 |
| Hemoglobin | 6.0 | 9.4 |
| Thrombosis/embolism | 6.0 | 3.1 |
| Platelets | 5.4 | 9.4 |
| Tumor pain | 4.8 | 6.3 |
| Dehydration | 4.2 | 9.4 |
| Constipation | 3.6 | 3.1 |
| Diarrhea without colostomy | 3.6 | 9.4 |
| Febrile neutropenia | 0.6 | 9.4 |
| Infection with grade3/4 neutropenia | 0.6 | 6.3 |